Nufymco
Ranibizumab biosimilar developed by Zydus Lifesciences. Reference product Lucentis.
About Nufymco
Nufymco is Zydus's ranibizumab, approved in the United States in December 2025 and interchangeable from the start. It was the first ranibizumab biosimilar from an Indian company to reach the United States, and one of Zydus's first US biosimilar approvals.
Status by market
United States · Nufymco
US Food and Drug AdministrationApprovedEuropean Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Nufymco holds an approval, these are the other ranibizumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| FDA | 3 | Bioeq (Cimerli / Ranivisio), Lupin (Ranluspec / Vislyfa), Samsung Bioepis (Byooviz) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Zydus Lifesciences: Exemptia / Cadalimab, Zydus aflibercept, Zydus bevacizumab, Zydus epoetin, Zydus follitropin alfa, Zydus peginterferon alfa-2b, Zydus pertuzumab, Zydus rituximab, Zydus teriparatide, Zydus trastuzumab.
Chronology
- FDADec 2025Approved by FDA
Sources
S001FDA, Biosimilar Product Information (approved biosimilars table) Primary (regulator)S016FDA Purple Book, monthly data downloads January to August 2026 Primary (regulator)
Planning ranibizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant